PROMBot-HSM-AF: protocol for a feasibility study of a chatbot-based platform to collect patient-reported outcomes after atrial fibrillation ablation - Scorecard - MDSpire
Clinical Scorecard: Feasibility Study Protocol for PROMBot-HSM-AF: A Chatbot-Driven Approach to Gather Patient-Reported Outcomes Following Atrial Fibrillation Ablation
At a Glance
Category
Detail
Condition
Atrial Fibrillation (AF)
Key Mechanisms
Chatbot-driven remote patient monitoring to gather patient-reported outcomes post-ablation.
Target Population
Patients undergoing catheter ablation for atrial fibrillation.
Care Setting
Tertiary hospital post-ablation follow-up.
Key Highlights
AF is the most prevalent sustained cardiac arrhythmia.
Catheter ablation is increasingly used as first-line therapy for AF.
15% to 20% of patients require reassessment in the first month post-ablation.
PROMBot-HSM-AF aims to enhance patient engagement and monitoring.
Study evaluates feasibility, usability, and acceptability of chatbot intervention.
Guideline-Based Recommendations
Diagnosis
AF diagnosis should consider associated cardiovascular comorbidities.
Management
Catheter ablation is recommended for selected patients with AF.
Monitoring & Follow-up
Remote patient monitoring may improve continuity of care.
Risks
AF is linked to increased risk of stroke and all-cause mortality.
Patient & Prescribing Data
Patients undergoing AF catheter ablation at Santa Marta Hospital.
Chatbot platform aims to systematically collect patient-reported outcomes.
Clinical Best Practices
Incorporate patient-reported outcome measures into follow-up care.
Utilize digital platforms for patient engagement and monitoring.
Ensure multidisciplinary collaboration for effective RPM implementation.
by Sérgio Laranjo, Pedro Silva Cunha, Federico Guede-Fernández, Eduarda Oliosi, Rita Contins, Pedro Dias, Catarina Silva, Ana Clara Félix, Mário Martins Oliveira, Ana Rita Londral
Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
